Description: Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Home Page: acceleratediagnostics.com
3950 South Country Club Road
Tucson,
AZ
85714
United States
Phone:
520 365 3100
Officers
| Name | Title |
|---|---|
| Mr. Jack Phillips | CEO, Pres & Director |
| Mr. Steve Reichling | Chief Financial Officer |
| Mr. Ron Price | Chief Commercial Officer of Americas |
| Dr. Lawrence Mertz | Chief Technology Officer |
| Laura Pierson | Investor Relations Officer |
| Mr. Michael Bridge | Sr. VP, Gen. Counsel & Sec. |
| Ms. Gretchen Strohminger | Sr. VP and Head of HR & Culture |
| Mr. Cherif Bousselham | Sr. VP & Head of Sales - EMEA |
| Ms. Laura Costa | Sr. VP & Head of Global Customer Support |
| Mr. John Meduri | Chief Strategy Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 4.9686 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 220 |